RECURRENT MARGINAL ZONE LYMPHOMA

This early-stage study is testing a combination of three drugs—obinutuzumab, venetoclax, and lenalidomide—in patients whose B-cell non-Hodgkin lymphoma has come back or hasn't responded to previous treatments. The main goal is to find the safest and most effective dose of the dru…

This study is testing the safety and effectiveness of combining two existing drugs, nivolumab and lenalidomide, for patients with non-Hodgkin or Hodgkin lymphoma that has come back or stopped responding to other treatments. The goal is to see if using these drugs together can bet…

This study is testing whether the immunotherapy drug nivolumab can help control blood cancers that have returned, stopped responding, or are still detectable after a patient has already received CAR-T cell therapy. It is for adults with specific types of lymphoma, leukemia, or mu…

This early-stage study is testing the safety and best dose of a new drug, pevonedistat, when given with an existing drug, ibrutinib. It is for adults with chronic lymphocytic leukemia or non-Hodgkin lymphoma that has come back or stopped responding to other treatments. The goal i…

This early-stage study is testing a new type of cellular immunotherapy for adults whose B-cell lymphoma or leukemia has come back. Doctors collect a patient's own immune cells, genetically modify them in a lab to better recognize and attack cancer cells, and then infuse them back…

This early-stage study is testing the safety and best dose of two drugs, ibrutinib and lenalidomide, when given together. It is for adults whose B-cell non-Hodgkin lymphoma has come back or has not responded to previous treatments. The goal is to see if combining these drugs is s…

This early-stage study is testing the safety and best dose of a three-drug combination for patients with slow-growing non-Hodgkin's lymphoma that has returned or not responded to prior treatment. The drugs work together to help the immune system attack cancer cells and block a pr…

This study is testing if adding a new drug called selinexor to the standard chemotherapy regimen (RCHOP) is safe and more effective for treating B-cell non-Hodgkin's lymphoma. It will first find the safest dose of the combination, then see how well it works for newly diagnosed pa…

This early-stage study is testing a new combination of three drugs for people whose non-Hodgkin's lymphoma has come back after prior treatment. The main goal is to find the safest and most effective dose of a new pill (PCI-32765) when given with two existing drugs (rituximab and …

This early-phase study is testing a new type of cell therapy for patients with high-risk or returning B-cell non-Hodgkin lymphoma. After receiving a stem cell transplant, patients get an infusion of their own immune cells that have been genetically modified in a lab to better fin…

This study is testing a personalized plan to manage cytomegalovirus (CMV), a common and potentially serious infection, in patients who have received a donor stem cell transplant for blood cancers or disorders. The plan involves closely monitoring the virus level and the patient's…

This study is testing a new type of personalized cell therapy for patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukemia that has come back or not responded to standard treatments. Doctors take a patient's own immune cells, genetically modify them to better tar…